BTX 1204A
Atopic Dermatitis (Canine & Human potential)
Pilot StudyCanine study enrolling in Australia/New Zealand; Positive pilot data
Key Facts
Indication
Atopic Dermatitis (Canine & Human potential)
Phase
Pilot Study
Status
Canine study enrolling in Australia/New Zealand; Positive pilot data
Company
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a global healthcare innovator focused on transforming the treatment landscape for common yet underserved dermatological conditions and infections. The company's key achievement is the FDA approval and US commercial launch of Sofdra™, its first-in-class topical anticholinergic for hyperhidrosis, which is also approved and launched in Japan and South Korea through partners. With a mature pipeline targeting acne, rosacea, atopic dermatitis, and antimicrobial resistance (MRSA), and led by a world-class team with extensive dermatology drug development and commercialization expertise, Botanix is strategically positioned to capture significant market opportunities.
View full company profile